Activated Clotting Time and Haemostatic Complications in Patients Receiving ECMO Support: A Systematic Review
<b>Background</b>: Extracorporeal membrane oxygenation (ECMO) requires systemic anticoagulation to prevent clotting, typically using unfractionated heparin (UFH). However, anticoagulation carries a bleeding risk, necessitating monitoring. Activated clotting time (ACT) is a commonly used...
Saved in:
Main Authors: | Daniel Schwaiger, Lukas Schausberger, Benedikt Treml, Dragana Jadzic, Nicole Innerhofer, Christoph Oberleitner, Zoran Bukumirić, Igor Spurnić, Sasa Rajsic |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-07-01
|
Series: | Journal of Cardiovascular Development and Disease |
Subjects: | |
Online Access: | https://www.mdpi.com/2308-3425/12/7/267 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Should I Change Anticoagulane in Veno-Venous ECMO?
by: Rabia Yılmaz, et al.
Published: (2025-08-01) -
Development of an extracorporeal pump for ECMO systems
by: A. P. Kuleshov, et al.
Published: (2025-01-01) -
PROTEOLYTIC ACTIVITY OF MILK-CLOTTING ENZYMES OF DIFFERENT ORIGIN
by: D. S. Myagkonosov, et al.
Published: (2022-03-01) -
PERIPHERAL VENO-ARTERIAL ECMO AS MECHANICAL CIRCULATORY SUPPORT BEFORE HEART TRANSPLANTATION
by: E. A. Spirina, et al.
Published: (2013-05-01) -
SUCCESSFUL TREATMENT OF A RECIPIENT WITH MASSIVE THROMBOSIS OF HEART TRANSPLANT LEFT CHAMBERS DURING EXTRACORPOREAL MEMBRANE OXYGENATION
by: V. N. Poptsov, et al.
Published: (2016-06-01)